<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alfuzosin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alfuzosin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alfuzosin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11477" href="/d/html/11477.html" rel="external">see "Alfuzosin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F131552"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Uroxatral</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865598"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Alvuzosin;</li>
<li>Auro-Alfuzosin;</li>
<li>SANDOZ Alfuzosin;</li>
<li>Xatral</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F131571"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha <sub>1</sub> Blocker</li></ul></div>
<div class="block doa drugH1Div" id="F131556"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64ef9771-0186-450c-8cac-9fbc347a4341">Benign prostatic hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia (monotherapy or combination therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In patients with moderate to severe predominant storage lower urinary tract symptoms, use in combination with beta-3 agonist or anticholinergic agent. In patients with a significantly enlarged prostate (prostate volume &gt;30 mL, prostate-specific antigen &gt;1.5 ng/mL, or palpable prostate enlargement on digital rectal exam), use in combination with 5-alpha reductase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34384237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34384237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg once daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f22af56-3956-4591-9dca-11295dae391d">Ureteral stone(s) expulsion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ureteral stone(s) expulsion (off-label use): Note:</b> Consider for use in patients with ureteral stones &gt;5 and ≤10 mm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620795','lexi-content-ref-27908918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620795','lexi-content-ref-27908918'])">Ref</a></span>). Although most evidence exists for distal ureteral stones, given the low side effect profile of alpha-blockers, may consider use in patients with stones in any location of ureter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27238616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27238616'])">Ref</a></span>). Additionally, may consider for use after shock wave lithotripsy to help pass stone fragments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27238615','lexi-content-ref-33179245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27238615','lexi-content-ref-33179245'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>10 mg once daily until stone passage or for up to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19193417','lexi-content-ref-20414396','lexi-content-ref-29620795','lexi-content-ref-21557836']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19193417','lexi-content-ref-20414396','lexi-content-ref-29620795','lexi-content-ref-21557836'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50989980"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe renal impairment (CrCl &lt;30 mL/minute).</p></div>
<div class="block doha drugH1Div" id="F50987324"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild hepatic impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe hepatic impairment (Child-Pugh class B or C): Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F131557"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F131522"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 2%), constipation (1% to 2%), dyspepsia (1% to 2%), nausea (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (6%), fatigue (3%), headache (3%), pain (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1% to 2%), pharyngitis (1% to 2%), sinusitis (1% to 2%), upper respiratory tract infection (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Cardiovascular: Hypotension, orthostatic hypotension, syncope</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, chest pain, edema, flushing, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (including cholestatic and hepatocellular), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Intraoperative floppy iris syndrome (with cataract surgery) (Settas 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis</p></div>
<div class="block coi drugH1Div" id="F131535"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to alfuzosin or any component of the formulation; moderate or severe hepatic impairment (Child-Pugh class B and C); concurrent use with potent CYP3A4 inhibitors (eg, itraconazole, ketoconazole, ritonavir)</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concurrent use with other alpha1-blockers</p></div>
<div class="block war drugH1Div" id="F131520"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angina: Discontinue if symptoms of angina occur or worsen.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha<sub>1</sub>-blockers; there appears to be no benefit in discontinuing alpha<sub>1</sub>-blocker therapy prior to surgery. May require modifications to surgical technique.</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension/syncope: May cause orthostatic hypotension and syncope within a few hours following administration; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug, PDE-5 inhibitors, or nitrates is introduced. Use with caution in patients with symptomatic orthostatic hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Priapism: Priapism has been associated with use (rarely); seek immediate medical assistance for erections lasting longer than 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with histories of tachyarrhythmia or with certain cardiovascular conditions, such as myocardial ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild hepatic impairment; contraindicated in moderate-to-severe impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate cancer: Rule out prostatic carcinoma before beginning therapy (many symptoms of BPH and prostate cancer are similar).</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: Alfuzosin has been shown to prolong the QT interval alone (minimal) and with other drugs with comparable effects on the QT interval (additive). Use with caution in patients with known QT prolongation (congenital or acquired).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warning/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Limitation of use: Not intended for use as an antihypertensive drug.</p></div>
<div class="block foc drugH1Div" id="F131530"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Uroxatral: 10 mg [contains hydrogenated castor oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block geq drugH1Div" id="F131518"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F131536"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Alfuzosin HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.15 - $5.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Uroxatral Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $32.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865599"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xatral: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block adm drugH1Div" id="F131532"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer immediately following a meal at the same time each day. Swallow tablet whole; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No IR formulation available; prazosin is the drug within class most similar in structure with an IR formulation available if needing to switch.</p></div>
<div class="block use drugH1Div" id="F131531"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Benign prostatic hyperplasia:</b> Treatment of signs and symptoms of benign prostatic hyperplasia.</p></div>
<div class="block off-label drugH1Div" id="F25720650"><span class="drugH1">Use: Off-Label: Adult</span><p>Ureteral stones, expulsion</p></div>
<div class="block cyt drugH1Div" id="F131566"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F131524"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Alfuzosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Alfuzosin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May increase the serum concentration of Alfuzosin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: Alpha1-Blockers (Uroselective) may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F131549"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases the extent of absorption. Management: Administer immediately following a meal at the same time each day.</p></div>
<div class="block pri drugH1Div" id="F131537"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies. </p></div>
<div class="block brc drugH1Div" id="F46022765"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if alfuzosin is present in breast milk.</p></div>
<div class="block dic drugH1Div" id="F131538"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take immediately following a meal.</p></div>
<div class="block mop drugH1Div" id="F131528"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">International Prostate Symptom Score (IPSS) (baseline and 4 to 12 weeks after treatment initiation); urinalysis (baseline); BP; prostate-specific antigen; objective and subjective signs of relief of benign prostatic hyperplasia and lower urinary tract symptoms (AUA [Lerner 2021]; manufacturer’s labeling).</p></div>
<div class="block pha drugH1Div" id="F131519"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">An antagonist of alpha<sub>1</sub>-adrenoreceptors in the lower urinary tract. Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha<sub>1</sub>-adrenoreceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockade of these adrenoreceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in BPH symptoms.</p></div>
<div class="block phk drugH1Div" id="F131534"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Decreased 50% under fasting conditions </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 3.2 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 82% to 90% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic, primarily via CYP3A4; metabolism includes oxidation, O-demethylation, and N-dealkylation; forms metabolites (inactive) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 49% following a meal </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 10 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 8 hours following a meal </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (69%); urine (24%; 11% as unchanged drug) </p></div>
<div class="block phksp drugH1Div" id="F51219954"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mean C<sub>max</sub> and AUC values were increased ~50% in patients with mild, moderate, or severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with moderate or severe hepatic impairment, clearance is decreased and plasma concentrations are increased 3- to 4-fold.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma concentrations in patients ≥75 years were ~35% greater than in those &lt;65 years.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F131539"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Alfosin xr | Uritab xl | Xatral</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dalfaz | Uroxatral</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alfasin | Alfumax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosine Sandoz | Xatral</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosine aurobindo | Xatral</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin Actavis | Alfuzosin Axapharm | Alfuzosin Cimex | Alfuzosin mepha | Alfuzosine uno zentiva | Xatral</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Flotral</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Uroxatral</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Nuo shu an | Wei ping | Xatral</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin aurobindo | Alfuzosin sandoz | Alfuzostad | Xatral</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin | Alfuzosin Acino | Alfuzosin aurobindo | Alfuzosin stada | Alfuzosin Winthrop | Alfuzosin zentiva | Urion | Urixatral uno | Uroxatral | Xatral</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin stada | Alfuzosin teva | Xatral</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alfetim | Alfuzosina aurobindo | Alfuzosina Ratiopharm | Alfuzosina teva | Bundisarin | Unibenestan</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Uritab xl | Xatral</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin HCL | Alfuzosin hcl orifarm | Alfuzosin Hydrochlorid Orifarm | Alfuzosin hydrochloride orion | Alfuzosin Hydrochloride Sandoz | Alfuzosin Hydrochloride Teva | Danafusin | Xatral</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosine Biogaran | Alfuzosine EG | Alfuzosine evolugen | Alfuzosine Isomed | Alfuzosine Merck | Alfuzosine Qualimed | Alfuzosine Ranbaxy | Alfuzosine rpg | Alfuzosine Sandoz | Alfuzosine Teva | Alfuzosine Winthrop | Alfuzosine zydus | Urion | Xatral</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin | Alfuzosin HCL | Alfuzosin ranbaxy | Besavar XL | Kelanu | Taurazil | Vasran | Xatral | Zochek</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alcinin | Alfural | Alfuzin | Alfuzosin/Norma | Alfuzosin/Teva | Ofuxal | Xatral | Zoprost | Zoratral xr</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin sandoz | Alfuzosina ph&amp;t | Apo alfuzosin | Xatral</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alfetim | Fetamozin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Alzmeran xl | Benprotan | Xatger | Xatral</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Alfu kal xl | Xatral</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alfman | Alfoo | Alfugress | Alfusin | Atful | Efzu | Emzosin | Flotral | Fual | Fulflo | Uralfin | Velfu | Zyalfa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosina aurobindo | Alfuzosina EG | Alfuzosina Mylan | Alfuzosina pensa | Alfuzosina Ranbaxy | Alfuzosina Ratiopharm | Alfuzosina Sandoz | Alfuzosina Winthrop | Faralzin | Mittoval | Xatral</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alfutor er | Alpros | Flotral | Xatral</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alfsin XL | Alfurix xl | Altral xl | Alzosin | Bearxat xl | Zaltrin xl | Zexatron | Zexatron XL</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Alfosin | Fuzocim | Uritab xl | Xatral</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosina ph&amp;t | Apo alfuzosin | Flotral | Fuzocim | Xatral</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin teva | Xatral</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Adenol lp | Flotral | Iprost | Uritab xl | Xatral</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alphatral | Ranplasia | Xatral</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alfutor er | Ranfuzosin | Xatral</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Fuzotral</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosine | Alfuzosine hcl | Alfuzosine HCl A | Alfuzosine HCl Aurobindo | Alfuzosine Hcl Merck | Alfuzosine hcl ratiopharm | Alfuzosine hcl sandoz | Alfuzosine Hydrochloride | Alfuzosinehydrochloride pch | Benestan | Mittoval | Urion | Xatral</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin mepha | Alfuzosin stada | Xatral</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Flotral | Xantral</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alfumax | Alfustad | Alfuzosin | Fozal | Profuzosin | Xatral</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alfuzid sr | Fuzo | Urobar | Xatral | Ztrol xl</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alfabax | Alfurion | Alfuzostad | Dalfaz | Dalfaz uno | Xatral</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin HCL | Uroxatral</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosina | Alfuzosina alter | Alfuzosina arrowblue | Alfuzosina aurobindo | Alfuzosina generis | Alfuzosina labesfal | Alfuzosina Ranbaxy | Alfuzosina teva | Benestan | Benestan ap</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Uroxatral | Xatral</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Alfosin XR | Uritab XL | Xatral XL</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alfuran mr</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alfuprost | Alfuprost mp | Alfuprost mr | Alfuzosin | Dalfas | Dalfaz sr</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Alfosin xr | Apo alfuzosin | Uritab xl | Xatral</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin Actavis | Alfuzosin ebb | Alfuzosin Hexal | Alfuzosin orion | Alfuzosin ranbaxy | Alfuzosin Ratiopharm | Alfuzosin sandoz | Alfuzosin stada | Alfuzosin teva | Alfuzosin Winthrop | Bundisarin | Danafusin | Lafunomyl | Urozosin | Xatral</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin | Ranfuzosin | Xatral</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alfuzostad | Xatral</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Alfuzosin Cimex | Urosine | Xaprost LP | Xatral</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alfutu | Xalfu | Xatral</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alfuzo XL | Azosin | Xatral</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alfirum</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Prostalen | Prosterol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Uroxatral</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Xatral</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Alanboss xl</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Alfuwin | Rantral | Xatral</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Alfutor er | Xatral</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Alfutor er</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19193417">
<a name="19193417"></a>Agrawal M, Gupta M, Gupta A, Agrawal A, Sarkari A, Lavania P. Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. <i>Urology</i>. 2009;73(4):706-709. doi:10.1016/j.urology.2008.11.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/19193417/pubmed" id="19193417" target="_blank">19193417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20414396">
<a name="20414396"></a>Ahmed AF, Al-Sayed AY. Tamsulosin versus alfuzosin in the treatment of patients with distal ureteral stones: prospective, randomized, comparative study. <i>Korean J Urol</i>. 2010;51(3):193-197. doi:10.4111/kju.2010.51.3.193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/20414396/pubmed" id="20414396" target="_blank">20414396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27238616">
<a name="27238616"></a>Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part I. <i>J Urol</i>. 2016b;196(4):1153-1160. doi:10.1016/j.juro.2016.05.090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/27238616/pubmed" id="27238616" target="_blank">27238616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27238615">
<a name="27238615"></a>Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part II. <i>J Urol</i>. 2016a;196(4):1161-1169. doi:10.1016/j.juro.2016.05.091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/27238615/pubmed" id="27238615" target="_blank">27238615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620795">
<a name="29620795"></a>Campschroer T, Zhu X, Vernooij RW, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. <i>Cochrane Database Syst Rev</i>. 2018;4(4):CD008509. doi:10.1002/14651858.CD008509.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/29620795/pubmed" id="29620795" target="_blank">29620795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21557836">
<a name="21557836"></a>Gurbuz MC, Polat H, Canat L, Kilic M, Caskurlu T. Efficacy of three different alpha 1-adrenergic blockers and hyoscine N-butylbromide for distal ureteral stones. <i>Int Braz J Urol.</i> 2011;37(2):195-200; discussion 201-2. doi:10.1590/s1677-55382011000200006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/21557836/pubmed" id="21557836" target="_blank">21557836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27908918">
<a name="27908918"></a>Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. <i>BMJ</i>. 2016;355:i6112. doi:10.1136/bmj.i6112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/27908918/pubmed" id="27908918" target="_blank">27908918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol</i>. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33179245">
<a name="33179245"></a>Oestreich MC, Vernooij RW, Sathianathen NJ, et al. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. <i>Cochrane Database Syst Rev</i>. 2020;11(11):CD013393. doi:10.1002/14651858.CD013393.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/33179245/pubmed" id="33179245" target="_blank">33179245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16498436">
<a name="16498436"></a>Settas G, Fitt AW. Intraoperative floppy iris syndrome in a patient taking alfuzosin for benign prostatic hypertrophy. <i>Eye (Lond)</i>. 2006;20(12):1431-1432. doi:10.1038/sj.eye.6702291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfuzosin-drug-information/abstract-text/16498436/pubmed" id="16498436" target="_blank">16498436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Uroxatral.1">
<a name="Uroxatral.1"></a>Uroxatral (alfuzosin) [prescribing information]. St. Michael, Barbados: Concordia Pharmaceuticals Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xatral.1">
<a name="Xatral.1"></a>Xatral (alfuzosin) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; January 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9105 Version 319.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
